Semaglutide
GLP-1 receptor agonist.
Evidence A
35 EDUCATIONAL ENTRIES
Know what the evidence says.
Grades describe the cited population and indication, not safety or suitability for an individual. Clinician review is pending. No entry creates a plan or recommends use.
Tirzepatide
GIP and GLP-1 receptor agonist.
Evidence A
Tesamorelin
Growth-hormone-releasing-hormone analogue.
Evidence A
Oxytocin
Peptide hormone acting on oxytocin receptors, including uterine muscle.
Evidence A
PT-141
Bremelanotide is a melanocortin receptor agonist.
Evidence A
SS-31
Elamipretide acts on mitochondrial cardiolipin; product-specific evidence matters.
Evidence B
Retatrutide
Investigational agonist of GLP-1, GIP and glucagon receptors.
Evidence B
Cagrilintide
Investigational long-acting amylin analogue.
Evidence B
Sermorelin
Growth-hormone-releasing-hormone analogue.
Evidence C
BPC-157
A human therapeutic mechanism is not established in this catalog; laboratory hypotheses do not establish clinical benefit.
Evidence D
TB-500
The research name can refer to a thymosin-beta-4 fragment; it is not interchangeable with full-length thymosin beta-4.
Evidence D
CJC-1295
Growth-hormone-releasing-hormone analogue; DAC and non-DAC naming must not be treated as interchangeable.
Evidence C
Ipamorelin
Growth-hormone secretagogue acting through the ghrelin receptor.
Evidence C
GHK-Cu
Copper-binding tripeptide; findings for one formulation cannot establish benefit or safety for another.
Evidence D
MOTS-C
Mitochondrial-derived peptide studied in metabolic signaling.
Evidence D
Melanotan II
Research melanocortin receptor agonist.
Evidence D
Thymosin Alpha-1
Peptide studied for immune modulation.
Evidence C
AOD-9604
Growth-hormone fragment studied in metabolic research.
Evidence D
KPV
Alpha-MSH-derived tripeptide studied in inflammatory signaling in cells and animal models.
Evidence D
LL-37
Human cathelicidin peptide involved in innate immune signaling.
Evidence D
Semax
A human therapeutic mechanism is not established in this catalog; laboratory hypotheses do not establish clinical benefit.
Evidence C
Selank
Tuftsin-derived research peptide studied in GABA-related gene expression.
Evidence D
DSIP
A human therapeutic mechanism is not established in this catalog; laboratory hypotheses do not establish clinical benefit.
Evidence D
Epithalon
A human therapeutic mechanism is not established in this catalog; laboratory hypotheses do not establish clinical benefit.
Evidence D
Dihexa
A human therapeutic mechanism is not established in this catalog; laboratory hypotheses do not establish clinical benefit.
Evidence D
MK-677
Ibutamoren is a nonpeptide growth-hormone secretagogue.
Evidence C
Kisspeptin
Peptide signaling through the reproductive hormone axis.
Evidence C
NAD+
A nonpeptide coenzyme involved in cellular redox reactions.
Evidence D
5-Amino-1MQ
Experimental nonpeptide NNMT inhibitor studied in animal metabolic research.
Evidence D
SLU-PP-332
Experimental nonpeptide estrogen-related-receptor agonist studied in mice.
Evidence D
FOXO4-DRI
Experimental peptide studied for disruption of FOXO4-p53 interactions in senescent cells.
Evidence D
GHRP-2
Growth-hormone-releasing peptide.
Evidence C
GHRP-6
Growth-hormone-releasing peptide.
Evidence C
Hexarelin
Growth-hormone-releasing peptide studied for pituitary hormone effects.
Evidence C
PEG-MGF
Pegylated growth-factor-related research peptide; product identity and human action are not established here.
Evidence D
No entries match.